InflaRx receives FDA emergency use authorization for Gohibic (vilobelimab) for treatment of critically Ill COVID-19 patients

Abivax appoints Marc de Garidel as Chief Executive Officer and interim Board Chair

Heidelberg Pharma presents new preclinical data from its proprietary ATAC technology platform at AACR Annual Meeting 2023

iOmx Therapeutics announces dosing of first patient with SIK inhibitor OMX-0407 in Phase I clinical trial

QUANTRO Therapeutics appoints industry expert Dr. Michael Bauer as Chief Executive Officer

Mainz Biomed expands corporate health program for ColoAlert with the addition of three new companies in Germany

Destiny Pharma: Landmark data published on successful NTCD-M3 gut colonisation after fidaxomicin administration

Carbios licensing documentation ready for worldwide industrial and commercial deployment of its PET biorecycling technology

Destiny Pharma: notice of full year results and investor presentation

ONWARD publishes first annual ESG summary